Zenas BioPharma, Inc.
corporate_fare Company Profile
Zenas BioPharma, Inc. (NASDAQ:ZBIO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 32 items for ZBIO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for ZBIO spans 10-Q, 8-K, 144, SCHEDULE 13D.
Recent high-impact activity:
- Zenas Q3 Loss Widens to $108.9M as R&D and Milestone Costs Jump; $647.1M Cash Funds Runway Into 2029
- Zenas Posts $647M Cash, EMA Validates Obexelimab MAA Ahead of May 2027 PDUFA
- Zenas BioPharma Reports Positive Phase 3 INDIGO Open-Label Extension Data for Obexelimab in IgG4-RD
- Affiliate Zebra Aggregator Files to Sell 1M Shares of Zenas BioPharma
- Zenas BioPharma Q2 2026: $673.9M Cash, FDA BLA Accepted, CFO Transition
Financial Snapshot
Short Interest & Short Volume
24.08 days to coverFINRA reported short interest of 11,354,403 shares in ZBIO as of the October 30, 2026 settlement, a 9.4% decrease from the prior period — about 24.1 days to cover at its recent average daily volume. On November 20, 2026, 82.9% of ZBIO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for ZBIO, detected from its recent SEC filings · based on capital-structure filings through 2026-11-06.
New $200M ATM Program Filed · Prior Program Exhausted and Terminated
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →